{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:47Z","timestamp":1793652407904,"version":"4.5.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehaf459","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:46:49Z","timestamp":1750492009000},"source":"Crossref","is-referenced-by-count":3,"title":["Mineralocorticoid receptor antagonists and hyperkalaemia: predictable, preventable, manageable, and reversible"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-5461","authenticated-orcid":false,"given":"Pedro","family":"Marques","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o , Porto ,","place":["Portugal"]},{"name":"Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Cardiovascular Research and Development Center (UnIC@RISE) , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm, Centre D'Investigations Cliniques-Plurith\u00e9matique, Universit\u00e9 de Lorraine , CHRU Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2025080111320932400_ehaf459-B1","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2025080111320932400_ehaf459-B2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025080111320932400_ehaf459-B3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025080111320932400_ehaf459-B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2025080111320932400_ehaf459-B5","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025080111320932400_ehaf459-B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025080111320932400_ehaf459-B7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","article-title":"Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes","volume":"9","author":"Packer","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2025080111320932400_ehaf459-B8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025080111320932400_ehaf459-B9","doi-asserted-by":"publisher","first-page":"ehaf258","DOI":"10.1093\/eurheartj\/ehaf258","article-title":"An incident hyperkalaemia risk model for CKD and T2D: development and validation based on the FIDELITY population","volume":"46","author":"Ferreira","year":"2025","journal-title":"Eur Heart J"},{"key":"2025080111320932400_ehaf459-B10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025080111320932400_ehaf459-B11","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025080111320932400_ehaf459-B12","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2025080111320932400_ehaf459-B13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"2025080111320932400_ehaf459-B14","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf459\/63919785\/ehaf459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf459\/63919785\/ehaf459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:32:18Z","timestamp":1754062338000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehaf459\/8220870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf459","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"ehaf459"}}